Aug 16, 2019 Oncolytics Biotech(R) Announces Closing of Its Public Offering of Common Shares and Warrants
Aug 14, 2019 CORRECTION: Oncolytics Biotech(R) Announces Pricing of Its USD $3.7M - CDN $4.9M Public Offering of Common Share and Warrants
Aug 14, 2019 Oncolytics Biotech(R) Announces Pricing of Its Public Offering of Common Share and Warrants
Aug 13, 2019 Oncolytics Biotech(R) Reports 2019 Second Quarter Financial Results and Operational Highlights
Jul 23, 2019 Oncolytics Biotech(R) Announces Preliminary AWARE-1 Trial Data Demonstrating Viral Replication and Promotion of Inflammation Following Systemic Administration of Pelareorep When Combined with Tecentriq(R)
Jun 5, 2019 Oncolytics Biotech (R) Announces Study to Investigate Combination of Pelareorep and Avelumab in Metastatic Breast Cancer in Collaboration with Merck KGaA, Darmstadt, Germany, and Pfizer
Jun 5, 2019 Oncolytics Biotech (R) to Host Conference Call to Discuss Co-Development Agreement with Pfizer and Merck KGaA
May 29, 2019 Oncolytics Biotech(R) to Present at the 9th Annual LD Micro Invitational Investor Conference
May 16, 2019 Oncolytics Biotech (R) Publishes Abstract Highlighting Additional Biomarker Analyses at the 2019 American Society of Clinical Oncology Annual Meeting
